TAVALISSE is a novel agent that addresses an unmet need in chronic ITP treatment
In chronic ITP, there are no easy choices after steroids fail1
Therapy selection for chronic ITP is complicated by multiple variables2
- ITP severity (extent of bleeding)
- Presentation of symptoms
- Inconsistent response
- Complications of therapies
- Future interventions (ie, surgery)
- Patient concerns
- Tolerability of side effects
The management of patients who fail corticosteroids is challenging. . . .
The International Consensus report lists more than 10 second-line therapeutic
options, including splenectomy, without indicating a preference.
TAVALISSE addresses an unmet need by bolstering the cITP treatment armamentarium
Targeting immune-mediated platelet destruction bolsters the treatment armamentarium